Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

Guido Rindi, Nicola Normanno, A. M. Rachiglio, M. Lambiase, E. Martinelli, F. Fenizia, C. Esposito, C. Roma, T. Troiani, D. Rizzi, F. Tatangelo, G. Botti, E. Maiello, G. Colucci, F. Ciardiello, F. Giuliani, G. Simone, A. Febbraro, E. Tommaselli, S. CinieriM. Criscuolo, A. Rinaldi, R. Bordonaro, M. Manusia, S. Romito, P. Bufo, G. Cartenì, M. Biglietto, O. Nappi, E. Montesarchio, P. Micheli, G. Nasti, N. Chicchinelli, A. Iannaccone, A. Russo, D. Cabibi, G. Tonini, A. Onetti Muda, G. Perrone, T. Latiano, P. Graziano, S. Pisconti, A. Sebastio

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
Original languageEnglish
Pages (from-to)1710-1714
Number of pages5
JournalAnnals of Oncology
Publication statusPublished - 2015

Keywords

  • cancer
  • colorectal

Fingerprint

Dive into the research topics of 'Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.'. Together they form a unique fingerprint.

Cite this